Aura Biosciences, Inc. (AURA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $6.40
- As of
Kresmion compiles this page from AURA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Aura Biosciences, Inc. (AURA): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-11.
See the full AURA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AURA on one page. Preview it with sample data, then open it live with a free account.
Preview the AURA dossierActive events for AURA
- high13F: funds added
3 tracked funds increased AURA this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 25.8%, EPS $-0.48 vs $-0.3815 estimate
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +71% to AURA (2026Q2)
- medium13F: new position
D. E. Shaw & Co., Inc. new position in AURA
- high13F: large reduction
Point72 Asset Management, L.P. cut 60% of AURA (2026Q1)
FREE, NO ACCOUNT
Every event on AURA, as it fires
You are seeing 5 of 8 events recorded on AURA since 2026-05-26.
The five above landed across 4 days. The other 3 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AURA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 05153U107 · 2026Q2 | $4.4M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 05153U107 · 2026Q2 | $1.2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 05153U107 · 2026Q2 | $479K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 05153U107 · 2026Q2 | $369K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 05153U107 · 2026Q2 | $127K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AURA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AURA against its peers
AURA's return on equity of -77.6% ranks in the 36th percentile of 20 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | AURA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 42.7M | n/a | 11 |
| Operating margin | n/a | -142.7% | n/a | 10 |
| Net margin | n/a | -145.4% | n/a | 10 |
| Return on equity | -77.6% | -44.8% | 36 | 20 |
Peers (21): ABUS, NVCT, BCAX, DSGN, SLDB, LXRX, PRME, ACHV, IMMX, GYRE, SGMT, WVE, DBVT, CRMD, SANA, FDMT, XOMA.D, PHAT, CADL, ANNX, CLYM. Left out: SLBT (no annual filing), ATTO (no annual filing), ANL (period gap), IAM (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (AURA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AURA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AURA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.